Arthritis News and Research

Latest Arthritis News and Research

APS summit focuses on Antiphospholipid Syndrome research

Antiphospholipid Syndrome (APS) is a condition that may be responsible for up to one-third of strokes in people under age 50, up to one-fifth of all cases of blood clots in large veins, and one-quarter of recurrent miscarriages. Nonetheless, relatively few randomized clinical trials have been conducted involving people with APS, and those completed have included small numbers of participants.

3 Nov 2010

Arthritis Foundation urges FDA to expeditiously create regulatory pathway for biosimilars

Arthritis Foundation patient advocate, Jan Wyatt, PhD, will provide oral testimony on behalf of the approximately 4 million Americans with inflammatory arthritis at a Food and Drug Administration (FDA) hearing today. The hearing will focus on issues and challenges associated with an approval pathway for biologic products that are highly similar "biosimilar" or interchangeable with FDA-licensed products.

3 Nov 2010

Amgen outlines key recommendations for implementing approval pathway for biosimilars

Amgen Senior Vice President of Research and Development Joe Miletich, M.D., Ph.D., will urge members of a U.S. Food and Drug Administration (FDA) panel charged with implementing a pathway for biosimilars to establish approval standards that ensure patient safety and follow a science-based approach.

3 Nov 2010

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company's therapeutic development programs, VIMOVO (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act.

3 Nov 2010

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Ligand Pharmaceuticals Incorporated today announced it has been awarded $1,955,834 in immediately available funds from the U.S. government under HR: 3590 - Patient Protection and Affordable Care Act. The award comprises separate payments of approximately $245,000 for each of eight drug development programs at Ligand.

2 Nov 2010

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).

2 Nov 2010

IRS awards RXi Pharmaceuticals four Therapeutic Discovery Project grants

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded four Therapeutic Discovery Project (TDP) grants, totaling $977,917, by the United States Internal Revenue Service (IRS) as part of the Patient Protection and Affordable Care Act of 2010.

2 Nov 2010

Rigel third quarter net income increases to $50.4 million

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2010.

2 Nov 2010

Eye transformer impacts JAK/STAT-signaling pathway response with microbial challenge

Scientists are keeping their eye on a new discovery published in the November 2011 print issue of the FASEB Journal (http://www.fasebj.org) that explains what causes some genes to go out of control. Scientists have identified a "cellular switch," called eye transformer, that controls the flow of information from chemical signals outside of the cell to genes in the cell nucleus.

2 Nov 2010

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

The American Association of Acupuncture and Oriental Medicine (AAAOM) and the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) are collaborating to respond to a recent report by British professor Edzard Ernst, published in The Guardian, claiming improperly trained acupuncture treatments have been the cause of deaths over the past 45 years.

2 Nov 2010

Positive results from linaclotide Phase 3 trial in patients with IBS-C

Almirall, S.A. and Ironwood Pharmaceuticals, Inc. today announced positive top-line results from a 26-week pivotal Phase 3 clinical trial assessing the efficacy and safety of once-daily dosing of linaclotide 266 mcg in patients with irritable bowel syndrome with constipation (IBS-C).

2 Nov 2010

Arthritis drugs also prevent post-operative cognitive decline: Study

Anti-inflammatory drugs currently used to treat diseases such as rheumatoid arthritis may also help prevent cognitive problems after surgery, according to a new study by researchers at Imperial College London and University of California, San Francisco (UCSF).

2 Nov 2010

XOMA receives final $2.0 million from Kaketsuken under antibody technology collaboration

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.

1 Nov 2010

KAST trial to assess Kiva vertebral augmentation treatment for painful VCFs due to osteoporosis

Physicians at The Medical College of Wisconsin are conducting the KAST clinical trial at Froedtert Hospital to assess the safety and effectiveness of a new vertebral augmentation treatment (Kiva) for painful vertebral compression fractures (VCFs) due to osteoporosis.

29 Oct 2010

CAN launches Highly Qualified Consumer Database about arthritis

Over 4 million Canadians suffer from arthritis, but only a tiny percentage of them are involved in influencing arthritis research in Canada. The Consumer Advisory Council (CAC) of the Canadian Arthritis Network (CAN) hopes to change that by launching a Highly Qualified Consumer (HQC) Database that will store information about Canadians willing to volunteer as consultants or collaborators to arthritis researchers.

29 Oct 2010

New findings on Th17 cells pave way for human cancer treatment protocol

A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.

29 Oct 2010

Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced top-line results from ACCORD COPD II, a 12-week Phase III study comparing the efficacy and safety of inhaled aclidinium bromide, an investigative bronchodilator, to placebo in 544 patients with moderate to severe COPD.

29 Oct 2010

Research on sheep population could help explain variation in vaccine protection

Strong immunity may play a key role in determining long life, but may do so at the expense of reduced fertility, a Princeton University study has concluded.

29 Oct 2010

Today's Op-Eds: Medicare rip-offs; Courts and the individual mandate; Accountable care

Instead of getting hung up on labels adopted in the heat of political battle, they should focus instead on Supreme Court precedents that found that taxes designed to influence behavior, like taxes to deter the sale of particularly dangerous firearms, were constitutional, provided they raised revenue in the process.

29 Oct 2010

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2010.

28 Oct 2010

Arthritis News and Research

Latest Arthritis News and Research

APS summit focuses on Antiphospholipid Syndrome research

Arthritis Foundation urges FDA to expeditiously create regulatory pathway for biosimilars

Amgen outlines key recommendations for implementing approval pathway for biosimilars

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

GSK's Revolade receives Japanese approval for treatment of chronic ITP

IRS awards RXi Pharmaceuticals four Therapeutic Discovery Project grants

Rigel third quarter net income increases to $50.4 million

Eye transformer impacts JAK/STAT-signaling pathway response with microbial challenge

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

Positive results from linaclotide Phase 3 trial in patients with IBS-C

Arthritis drugs also prevent post-operative cognitive decline: Study

XOMA receives final $2.0 million from Kaketsuken under antibody technology collaboration

KAST trial to assess Kiva vertebral augmentation treatment for painful VCFs due to osteoporosis

CAN launches Highly Qualified Consumer Database about arthritis

New findings on Th17 cells pave way for human cancer treatment protocol

Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD

Research on sheep population could help explain variation in vaccine protection

Today's Op-Eds: Medicare rip-offs; Courts and the individual mandate; Accountable care

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Arthritis News and Research

Latest Arthritis News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in